Treatment with pirfenidone suppressed chronic intermittent hypoxia-augmented lung fibrosis in BLM-treated mice by upregulating Nrf2 and downregulating NF-κB [95]. The gene discussed is NFKB1; the disease is pulmonary fibrosis.